CN116535329A - Nobin类轴手性联芳基化合物的合成方法及其化合物 - Google Patents
Nobin类轴手性联芳基化合物的合成方法及其化合物 Download PDFInfo
- Publication number
- CN116535329A CN116535329A CN202310335538.7A CN202310335538A CN116535329A CN 116535329 A CN116535329 A CN 116535329A CN 202310335538 A CN202310335538 A CN 202310335538A CN 116535329 A CN116535329 A CN 116535329A
- Authority
- CN
- China
- Prior art keywords
- compound
- nobin
- biaryl compound
- chiral
- axial chiral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 biaryl compound Chemical class 0.000 title claims abstract description 55
- 150000001875 compounds Chemical class 0.000 title claims abstract description 7
- 238000010189 synthetic method Methods 0.000 title claims description 9
- 238000000034 method Methods 0.000 claims abstract description 29
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000001308 synthesis method Methods 0.000 claims abstract description 14
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 7
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 229940126214 compound 3 Drugs 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 238000007259 addition reaction Methods 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 229940125782 compound 2 Drugs 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- 125000005841 biaryl group Chemical group 0.000 claims 2
- 229940125904 compound 1 Drugs 0.000 claims 1
- HIXQCPGXQVQHJP-UHFFFAOYSA-N nobin Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3N)=C(O)C=CC2=C1 HIXQCPGXQVQHJP-UHFFFAOYSA-N 0.000 abstract description 14
- 239000003054 catalyst Substances 0.000 abstract description 6
- 230000002194 synthesizing effect Effects 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000003513 alkali Substances 0.000 abstract description 2
- 125000000524 functional group Chemical group 0.000 abstract description 2
- 238000007040 multi-step synthesis reaction Methods 0.000 abstract description 2
- 229910000510 noble metal Inorganic materials 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 abstract description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 79
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 28
- 238000005481 NMR spectroscopy Methods 0.000 description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 28
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 125000005605 benzo group Chemical group 0.000 description 9
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 150000005347 biaryls Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 230000005311 nuclear magnetism Effects 0.000 description 4
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 150000003624 transition metals Chemical class 0.000 description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
- B01J31/0234—Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
- B01J31/0255—Phosphorus containing compounds
- B01J31/0257—Phosphorus acids or phosphorus acid esters
- B01J31/0258—Phosphoric acid mono-, di- or triesters ((RO)(R'O)2P=O), i.e. R= C, R'= C, H
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/24—Anthracenes; Hydrogenated anthracenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/584—Recycling of catalysts
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
本发明提供了NOBIN类轴手性联芳基化合物的合成方法及其化合物。该合成方法通过手性磷酸催化剂催化1,3‑氧氮杂桥联联芳基化合物的方法构建NOBIN类轴手性联芳基化合物,一步合成,较已报道的方法原料需要多步骤合成,提高了原子经济性和步骤经济性,降低了成本。直接使用手性磷酸为催化剂,避免金属盐与强碱的使用,增加了产物所含官能团的多样性;同时避免贵金属的使用,有利于降低成本。而且该合成方法其具有产率高、对映选择性好等特点,与已有方法相比更为绿色环保,应用性更强,为NOBIN类轴手性联芳基化合物的合成提供了一种经济实用的新方法。
Description
技术领域
本发明属于有机合成技术领域,尤其涉及NOBIN类轴手性联芳基化合物的合成方法及其化合物。
背景技术
NOBIN类轴手性联芳基骨架是一类重要的结构单元,广泛存在于天然产物、药物分子以及手性催化剂中。目前,通过不对称催化反应合成NOBIN类轴手性联芳基化合物有以下几类方法:(1)通过去对称化策略合成NOBIN类轴手性联芳基化合物;(2)通过过渡金属催化的氧化交叉偶联反应合成NOBIN类轴手性联芳基化合物;(3)通过动力学拆分策略合成NOBIN类轴手性联芳基化合物;(4)通过共轭加成策略合成NOBIN类轴手性联芳基化合物。然而,以上四种方法存在底物适用范围窄、产率低、或采用金属催化剂等诸多问题。因此,进一步开发NOBIN类轴手性联芳基化合物的新型、高效、环保的合成方法具有极其重要的研究价值。
发明内容
本发明的目的在于,针对现有技术的上述不足,设计和研发了NOBIN类轴手性联芳基化合物的合成新方法及其化合物。
为实现上述目的,本发明采用如下的技术方案:本发明提供了一种NOBIN类轴手性联芳基化合物的合成方法,通过手性磷酸化合物1催化1,3-氧氮杂桥联联芳基化合物2与水的对映选择性加成反应,制得NOBIN类轴手性联芳基化合物3,该合成方法的反应方程式为:
所述手性磷酸化合物的结构式如下:
其中,R1,R2,R3均选自烷基、卤素、硝基或芳基;R为对-金刚烷基苯基。
进一步的,所述1,3-氧氮杂桥联联芳基化合物与水的摩尔比为1:2.8。
进一步的,所述1,3-氧氮杂桥联联芳基化合物与所述手性磷酸化合物的摩尔比为1:0.1。
进一步的,所述溶剂为无水环己烷,所述无水环己烷。
进一步的,所述无水环己烷与所述1,3-氧氮杂桥联联芳基化合物体积摩尔比为2mL:0.1mmol。
进一步的,所述合成方法的反应条件:温度为20℃~25℃,反应时间为1~7d。
进一步的,所述合成方法制得的制得NOBIN类轴手性联芳基化合物3为白色固体。
进一步的,所述NOBIN类轴手性联芳基化合物的收率不低于98%。
本发明的第二目的是提供采用上述合成方法制备的到的NOBIN类轴手性联芳基化合物。
进一步的,所述NOBIN类轴手性联芳基化合物的对应体过量值不低于90%。
与现有技术比较,本发明提供的技术方案带来的有益效果是:
(1)本发明通过手性磷酸催化剂催化1,3-氧氮杂桥联联芳基化合物的方法构建NOBIN类轴手性联芳基化合物,一步合成,较已报道的方法原料需要多步骤合成,提高了原子经济性和步骤经济性,降低了成本。而且该合成方法其具有产率高、对映选择性好等特点,与已有方法相比更为绿色环保,应用性更强。
(2)直接使用手性磷酸为催化剂,避免金属盐与强碱的使用,增加了产物所含官能团的多样性;同时避免贵金属的使用,有利于降低成本。
(3)本发明的合成方法具有反应条件温和、操作简便、原料来源广泛、产品利用价值高和有利于工业化生产等特点,为NOBIN类轴手性联芳基化合物的合成提供了一种经济实用的新方法。
附图说明
图1为本发明化合物的合成路线图;
图2和图3分别为实施例1产物的核磁氢谱图和核磁碳谱图;
图4和图5分别为实施例2产物的核磁氢谱图和核磁碳谱图;
图6和图7分别为实施例3产物的核磁氢谱图和核磁碳谱图;
图8和图9分别为实施例5产物的核磁氢谱图和核磁碳谱图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面结合附图和具体实施例,对本发明的具体实施方式作进一步详细描述。实施例中未注明具体技术或条件的,按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。
本发明用到的手性磷酸为R为对-金刚烷基苯基。
实施例1
如图1所示的合成路线,本实施例的1,3-氧氮杂桥联联芳基化合物1a为6-phenylbenzo[f]naphtho[2,1-d][1,3]oxazepine 1a(6-苯基苯并[f]萘并[2,1-d][1,3]氧氮杂/>)。
向反应瓶中加入手性磷酸2a(10mol%,7.35mg)、1,3-氧氮杂桥联联芳基化合物1a(0.1mmol,32mg)和无水环己烷(2ml),搅拌2-3分钟,再滴加水(5μl),室温搅拌反应(1-7天)后直接过滤分离得到目标产物((R)-N-(1-(2-羟基苯基)萘-2-基)苯甲酰胺)3a。白色固体,99%产率,92%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=17.54min,tmajor=20.68min,)。
如图2和图3所示,本实施例产物的核磁及质谱数据如下:
1H NMR(500MHz,DMSO):δ9.77(s,1H),9.21(s,1H),7.97(d,J=8.3Hz,3H),7.67(d,J=7.6Hz,2H),7.59–7.38(m,6H),7.32(t,J=7.9Hz,1H),7.18(d,J=7.5Hz,1H),7.09(d,1H),6.95(t,J=7.4Hz,1H)。13C NMR(126MHz,DMSO)δ165.4,155.3,135.0,133.8,132.8,132.6,132.1,131.7,129.9,129.6,129.0,128.3,128.0,127.4,126.6,126.3,125.6,124.6,122.6,119.7,116.3.HRMS(ESI,m/z):计算值[M+Na]+:362.1151,实测值:362.1150。
实施例2
合成方法与实施例1基本相同,不同之处为:1,3-氧氮杂桥联联芳基化合物1a为6-(4-chlorophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepine(6-(4-氯苯基)苯并[f]萘并[2,1-d][1,3]氧氮杂/>)。
得到目标产物((R)-4-氯-N-(1-(2-羟基苯基)萘-2-基)苯甲酰胺)3a。白色固体,99%产率,98%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=22.46min,tmajor=26.74min)。
如图4和图5所示,本实施例产物的核磁及质谱数据如下:
1H NMR(500MHz,DMSO):δ9.66(s,1H),9.42(s,1H),7.97(d,J=8.6Hz,2H),7.84(d,J=8.8Hz,1H),7.69(d,J=8.5Hz,2H),7.55–7.39(m,5H),7.32–7.25(m,1H),7.18–7.11(m,1H),7.05(d,J=8.1Hz,1H),6.92(t,J=7.5Hz,1H).13C NMR(126MHz,DMSO):δ164.7,155.3,136.8,133.8,133.7,132.8,132.5,131.8,130.7,129.8,129.5,129.0,128.3,127.9,126.5,126.4,125.7,125.3,122.7,119.5,116.2.HRMS(ESI,m/z):计算值[M+H]+:374.0942,实测值:374.0940。
实施例3
合成方法与实施例1基本相同,不同之处为:1,3-氧氮杂桥联联芳基化合物1a为6-(4-nitrophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepine(6-(4-硝基苯基)苯并[f]萘并[2,1-d][1,3]氧氮杂/>)。
得到目标产物((R)-N-(1-(2-羟基苯基)萘-2-基)-4-硝基苯甲酰胺)3a。白色固体,99%产率,98%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=35.79min,tmajor=38.48min)。
如图6和图7所示,本实施例产物的核磁及质谱数据如下:
1H NMR(500MHz,DMSO):δ9.79(s,1H),9.58(s,1H),8.28(d,J=8.3Hz,2H),7.99(d,J=8.4Hz,2H),7.90(d,J=8.2Hz,2H),7.77(d,J=8.5Hz,1H),7.47(dp,J=21.5,7.8,7.4Hz,3H),7.27(t,J=7.9Hz,1H),7.14(d,J=7.5Hz,1H),7.03(d,J=8.0Hz,1H),6.90(t,J=7.5Hz,1H)..13C NMR(126MHz,DMSO):δ164.4,155.4,149.5,140.8,133.4,132.7,132.4,132.1,131.7,129.8,129.2,128.3,128.0,126.5,126.5,125.9,125.8,124.0,122.8,119.4,116.2.HRMS(ESI+):计算值[M+Na]+:407.1002,实测值:407.0997。
实施例4
合成方法与实施例1基本相同,不同之处为:1,3-氧氮杂桥联联芳基化合物1a为6-(4-bromophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepine(6-(4-溴苯基)苯并[f]萘并[2,1-d][1,3]氧氮杂/>)。
得到目标产物((R)-4-溴-N-(1-(2-羟基苯基)萘-2-基)苯甲酰胺)3a。白色固体,99%产率,96%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=21.6min,tmajor=24.94min)。
1H NMR(500MHz,DMSO):δ9.65(s,1H),9.42(s,1H),7.97(d,J=8.4Hz,2H),7.84(d,J=8.8Hz,1H),7.70–7.55(m,4H),7.53–7.37(m,3H),7.28(t,J=7.7Hz,1H),7.14(d,J=7.5Hz,1H),7.04(d,J=8.1Hz,1H),6.91(t,J=7.4Hz,1H).13C NMR(126MHz,DMSO):δ164.9,155.3,134.1,133.6,132.8,132.5,131.9,131.8,130.7,129.8,129.7,128.3,127.9,126.5,126.4,125.7,125.7,125.3,122.7,119.5,116.2.HRMS(ESI+):计算值[M+H]+:418.0437,实测值:418.0433。
实施例5
合成方法与实施例1基本相同,不同之处为:6-(thiophen-2-yl)benzo[f]naphtho[2,1-d][1,3]oxazepine(6-(噻吩-2-基)苯并[f]萘并[2,1-d][1,3]氧氮杂)。
得到目标产物((R)-N-(1-(2-羟基苯基)萘-2-基)噻吩-2-甲酰胺)。白色固体,99%产率,94%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=17.26min,tmajor=20.94min)。
如图8和图9所示,本实施例产物的核磁及质谱数据如下:
1H NMR(500MHz,DMSO):δ9.75(s,1H),9.19(s,1H),8.00–7.94(m,2H),7.90(d,J=8.8Hz,1H),7.81(dd,J=5.0,1.2Hz,1H),7.53–7.47(m,2H),7.45–7.40(m,2H),7.31(td,J=7.8,1.8Hz,1H),7.18–7.11(m,2H),7.07(dd,J=8.2,1.2Hz,1H),6.94(td,J=7.4,1.2Hz,1H).13C NMR(126MHz,DMSO):δ160.1,155.3,139.9,133.3,132.8,132.6,132.0,131.7,129.9,129.9,129.0,128.5,128.3,128.0,126.6,126.4,125.6,124.74,122.53,119.6,116.3.HRMS(ESI+):计算值[M+Na]+:368.0716,实测值:368.0715。
实施例6
合成方法与实施例1基本相同,不同之处为:6-(furan-2-yl)benzo[f]naphtho[2,1-d][1,3]oxazepine(6-(呋喃-2-基)苯并[f]
萘并[2,1-d][1,3]氧氮杂
得到目标产物((R)-N-(1-(2-羟基苯基)萘-2-基)呋喃-2-甲酰胺)。白色固体,99%产率,94%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=18.32min,tmajor=22.48min)。
1H NMR(500MHz,DMSO):δ9.91(s,1H),8.85(s,1H),8.15(d,J=8.8Hz,1H),7.97(dd,J=12.4,8.5Hz,2H),7.81–7.78(m,1H),7.50–7.33(m,4H),7.19–7.10(m,3H),6.99(td,J=7.4,1.1Hz,1H),6.65(dd,J=3.5,1.8Hz,1H).13C NMR(126MHz,DMSO):δ156.1,155.3,147.6,146.2,133.0,132.8,132.6,131.4,130.3,128.3,128.2,127.7,126.7,126.1,125.5,122.8,121.9,119.9,116.5,115.4,112.9.HRMS(ESI+):计算值[M+Na]+:352.0944,实测值:352.0942。
实施例7
合成方法与实施例1基本相同,不同之处为:6-(3-bromophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepine(6-(3-溴苯基)苯并[f]萘并[2,1-d][1,3]氧氮杂)。
得到目标产物(R)-3-溴-N-(1-(2-羟基苯基)萘-2-基)苯甲酰胺)3a。白色固体,99%产率,96%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=17.32min,tmajor=20.6min)。
1H NMR(500MHz,DMSO):δ9.64(s,1H),9.50(s,1H),7.98(d,J=8.5Hz,2H),7.84-7.78(m,2H),7.73(d,J=8.0Hz,1H),7.67(d,J=7.7Hz,1H),7.45(dt,J=24.3,8.7Hz,4H),7.29(d,J=7.9Hz,1H),7.15(d,J=7.6Hz,1H),7.06(d,J=8.2Hz,1H),6.93(t,J=7.7Hz,1H).13C NMR(126MHz,DMSO-d6):δ164.5,155.4,137.3,134.6,133.6,132.7,132.5,131.9,131.1,131.1,130.5,129.8,128.3,128.0,126.7,126.5,126.5,125.8,125.5,122.8,122.1,119.4,116.2.HRMS(ESI+):计算值[M+H]+:418.0437,实测值:418.0434。
实施例8
合成方法与实施例1基本相同,不同之处为:6-(3-chlorophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepine(6-(3-氯苯基)苯并[f]萘并[2,1-d][1,3]氧氮杂)。
得到目标产物((R)-3-氯-N-(1-(2-羟基苯基)萘-2-基)苯甲酰胺)3a。白色固体,99%产率,94%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=15.95min,tmajor=18.92min)。
1H NMR(500MHz,DMSO):1H NMR(500MHz,DMSO)δ9.64(s,1H),9.50(s,1H),7.98(d,J=8.4Hz,2H),7.82(d,J=8.8Hz,1H),7.69–7.57(m,3H),7.52–7.40(m,4H),7.29(td,J=7.7,1.7Hz,1H),7.15(dd,J=7.6,1.8Hz,1H),7.05(d,J=8.1Hz,1H),6.95–6.89(m,1H).13CNMR(126MHz,DMSO):δ164.5,155.4,137.1,133.6,133.6,132.7,132.5,131.9,131.7,131.0,130.9,129.8,128.3,127.9,127.6,126.5,126.5,126.3,125.7,125.5,122.7,119.4,116.2.HRMS(ESI+):计算值[M+H]+:374.0942,实测值:374.0940。
实施例9
合成方法与实施例1基本相同,不同之处为:6-(2-chlorophenyl)benzo[f]naphtho[2,1-d][1,3]oxazepine(6-(2-氯苯基)苯并[f]萘并[2,1-d][1,3]氧氮杂)。
得到目标产物((R)-2-氯-N-(1-(2-羟基苯基)萘-2-基)苯甲酰胺)3a。白色固体,99%产率,94%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=23.27min,tmajor=26.48min)。
1H NMR(500MHz,DMSO)δ9.51(s,1H),9.44(s,1H),7.98(t,J=8.1Hz,2H),7.90(d,J=8.8Hz,1H),7.52–7.39(m,5H),7.34(dq,J=17.3,8.6,8.0Hz,3H),7.15(d,J=7.5Hz,1H),7.04(d,J=8.2Hz,1H),6.96(t,J=7.5Hz,1H).13C NMR(126MHz,DMSO):δ165.4,155.6,136.7,133.4,132.8,132.5,131.8,131.6,130.7,130.3,130.1,129.8,129.5,128.2,128.0,127.5,126.5,126.4,125.7,125.1,122.7,119.5,116.1.HRMS(ESI+):计算值[M+H]+:374.0942,实测值:374.0940。
实施例10
合成方法与实施例1基本相同,不同之处为:6-(4-chlorophenyl)-3-methoxybenzo[f]naphtho[2,1-d][1,3]oxazepine(6-(4-氯苯基)-3-甲氧基苯并[f]萘并[2,1-d][1,3]氧氮杂)。
得到目标产物((R)-4-氯-N-(1-(2-羟基-4-甲氧基苯基)萘-2-基)苯甲酰胺)3a。白色固体,93%产率,96%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=22.41min,tmajor=27.59min).
1H NMR(500MHz,DMSO):δ9.74(s,1H),9.36(s,1H),7.95(d,J=8.7Hz,2H),7.87(d,J=8.9Hz,1H),7.73(d,J=8.1Hz,2H),7.55(d,J=8.1Hz,2H),7.52 -7.39(m,3H),7.06(d,J=8.3Hz,1H),6.62(s,1H),6.58 -6.48(m,1H),3.76(s,3H).13C NMR(126MHz,DMSO):δ164.6,160.6,156.3,136.8,133.9,133.8,133.1,133.1,131.8,130.1,129.5,129.0,128.2,127.7,126.5,126.4,125.6,125.0,115.1,105.3,101.9,55.4.HRMS(ESI+):计算值[M+Na]+:426.0867,实测值:426.0864。
实施例11
合成方法与实施例1基本相同,不同之处为:6-(4-chlorophenyl)anthra[2,1-d]benzo[f][1,3]oxazepine(6-(4-氯苯基)蒽[2,1-d]苯并[f][1,3]氧氮杂)。
得到目标产物((R)-4-氯-N-(1-(2-羟基苯基)蒽-2-基)苯甲酰胺)3a。白色固体,93%产率,96%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=19.49min,tmajor=22.99min)。
1H NMR(500MHz,DMSO):δ9.74(s,1H),9.46(s,1H),8.64(s,1H),8.15(d,J=9.1Hz,1H),8.12 -8.03(m,2H),7.87(dd,J=16.3,8.7Hz,2H),7.72(d,J=8.1Hz,2H),7.58-7.42(m,4H),7.35(t,J=7.8Hz,1H),7.24(d,J=7.5Hz,1H),7.11(d,J=8.2Hz,1H),6.98(t,J=7.4Hz,1H).13C NMR(126MHz,DMSO):δ164.8,155.5,136.9,133.7,133.1,132.6,131.6,131.2,131.1,130.3,130.0,129.9,129.6,129.0,128.6,128.3,128.2,126.7,126.2,126.0,125.6,124.9,122.8,119.7,116.5.HRMS(ESI+):计算值[M+Na]+:446.0918,实测值:446.0915。
实施例12
合成方法与实施例1基本相同,不同之处为:6-(4-chlorophenyl)-3-methoxybenzo[f]naphtho[2,1-d][1,3]oxazepine(6-(4-氯苯基)-3-甲氧基苯并[f]萘并[2,1-d][1,3]氧氮杂)。
得到目标产物((R)-4-氯-N-(1-(2-羟基-3-甲氧基苯基)萘-2-基)苯甲酰胺)3a。白色固体,96%产率,98%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=30.59min,tmajor=51.91min)。
1H NMR(500MHz,DMSO):δ9.35(s,1H),8.83(s,1H),7.97(dd,J=8.5,3.2Hz,2H),7.86(d,J=8.8Hz,1H),7.69(dd,J=8.6,2.3Hz,2H),7.54-7.45(m,3H),7.42(d,J=4.5Hz,2H),7.06(dd,J=8.2,1.5Hz,1H),6.89(t,J=7.9Hz,1H),6.77 -6.72(m,1H),3.87(s,3H).13C NMR(126MHz,DMSO):δ164.8,148.3,144.5,136.8,133.8,133.6,132.6,131.7,130.2,129.5,129.0,128.2,128.0,126.5,126.5,125.7,125.1,123.9,123.0,119.4,111.9,56.3。HRMS(ESI+):计算值[M+Na]+:426.0867,实测值:426.0867。
实施例13
合成方法与实施例1基本相同,不同之处为:6-(4-chlorophenyl)-12-methoxybenzo[f]naphtho[2,1-d][1,3]oxazepine(6-(4-氯苯基)-12-甲氧基苯并[f]萘并[2,1-d][1,3]氧氮杂)。
得到目标产物((R)-4-氯-N-(1-(2-羟基苯基)-7-甲氧基萘-2-基)苯甲酰胺)3a。白色固体,99%产率,92%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=10.76min,tmajor=12.32min)。
1H NMR(500MHz,DMSO):δ9.69(s,1H),9.35(s,1H),7.90(dd,J=8.9,4.1Hz,2H),7.69(t,J=9.2Hz,3H),7.52(d,J=8.2Hz,2H),7.28(t,J=7.6Hz,1H),7.20 -7.14(m,2H),7.05(d,J=8.1Hz,1H),6.92(t,J=7.4Hz,1H),6.79(d,J=2.6Hz,1H),3.64(s,3H).13C NMR(126MHz,DMSO):δ164.6,157.7,155.2,136.8,134.2,134.1,133.8,132.5,130.01,129.8,129.5,129.4,129.0,127.7,127.3,122.8,122.7,119.6,117.5,116.3,105.6,55.2.HRMS(ESI+):计算值[M+Na]+:426.0867,实测值:426.0865。
实施例14
合成方法与实施例1基本相同,不同之处为:6-(4-chlorophenyl)-11-methoxybenzo[f]naphtho[2,1-d][1,3]oxazepine(6-(4-氯苯基)-11甲氧基苯并[f]萘并[2,1-d][1,3]氧氮杂)。
得到目标产物((R)-4-氯-N-(1-(2-羟基苯基)-6-甲氧基萘-2-基)苯甲酰胺)3a。白色固体,99%产率,92%对映体过量值,对映体过量值通过高效液相色谱的方法测定(测试条件:IA手性柱,正己烷/异丙醇=90/10,流速=1.0mL/min,波长=254nm,tminor=28.61min,tmajor=38.85min)。
1H NMR(500MHz,DMSO):δ9.65(s,1H),9.41(s,1H),7.87(d,J=8.8Hz,1H),7.74(d,J=8.8Hz,1H),7.69(d,J=8.2Hz,2H),7.52(d,J=8.4Hz,2H),7.39(d,J=2.6Hz,1H),7.36(d,J=9.2Hz,1H),7.27(td,J=7.7,1.7Hz,1H),7.13(d,J=7.5Hz,1H),7.10(dd,J=9.2,2.6Hz,1H),7.03(d,J=8.1Hz,1H),6.89(t,J=7.4Hz,1H),3.89(s,3H).13C NMR(126MHz,DMSO):δ164.8,157.3,155.3,136.7,133.8,133.3,132.4,131.6,131.3,129.7,129.5,128.9,128.1,128.0,126.8,126.1,123.0,119.43,118.96,116.2,106.5,55.6.HRMS(ESI+):计算值[M+H]+:404.1048,实测值:404.1044。
在不冲突的情况下,本文中上述实施例及实施例中的特征可以相互结合。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种NOBIN类轴手性联芳基化合物的合成方法,其特征在于,在溶剂中通过手性磷酸化合物2催化1,3-氧氮杂桥联联芳基化合物1与水的对映选择性加成反应,制得NOBIN类轴手性联芳基化合物3,该合成方法的反应方程式为:
所述手性磷酸化合物的结构式如下:
其中,R1,R2,R3均选自烷基、卤素、硝基或芳基;R为对-金刚烷基苯基。
2.如权利要求1所述的合成方法,其特征在于,所述1,3-氧氮杂桥联联芳基化合物与水的摩尔比为1:2.8。
3.如权利要求2所述的合成方法,其特征在于,所述1,3-氧氮杂桥联联芳基化合物与所述手性磷酸化合物的摩尔比为1:0.1。
4.如权利要求3所述的合成方法,其特征在于,所述溶剂为无水环己烷。
5.如权利要求4所述的合成方法,其特征在于,所述无水环己烷与所述1,3-氧氮杂桥联联芳基化合物体积摩尔比为2mL:0.1mmol。
6.如权利要求5所述的合成方法,其特征在于,所述合成方法的反应条件:温度为20℃~25℃,反应时间为1~7d。
7.如权利要求6所述的合成方法,其特征在于,所述合成方法制得的制得NOBIN类轴手性联芳基化合物为白色固体。
8.如权利要求6所述的合成方法,其特征在于,所述NOBIN类轴手性联芳基化合物的收率不低于98%。
9.一种NOBIN类轴手性联芳基化合物,其特征在于,采用如权利要求1-8中任一项所述的合成方法制得。
10.如权利要求9所述的一种NOBIN类轴手性联芳基化合物,其特征在于,所述NOBIN类轴手性联芳基化合物的对应体过量值不低于90%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310335538.7A CN116535329B (zh) | 2023-03-30 | 2023-03-30 | Nobin类轴手性联芳基化合物的合成方法及其化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310335538.7A CN116535329B (zh) | 2023-03-30 | 2023-03-30 | Nobin类轴手性联芳基化合物的合成方法及其化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116535329A true CN116535329A (zh) | 2023-08-04 |
CN116535329B CN116535329B (zh) | 2024-09-17 |
Family
ID=87455021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310335538.7A Active CN116535329B (zh) | 2023-03-30 | 2023-03-30 | Nobin类轴手性联芳基化合物的合成方法及其化合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116535329B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109535018A (zh) * | 2018-12-10 | 2019-03-29 | 南方科技大学 | 一种手性磷酸盐催化合成联萘酚胺的方法 |
CN111217803A (zh) * | 2020-01-14 | 2020-06-02 | 商洛学院 | 一种小分子oled电子传输材料及其制备方法与应用 |
CN112920072A (zh) * | 2021-01-27 | 2021-06-08 | 山东大学 | Nobin类联芳基化合物及其合成方法 |
CN114957103A (zh) * | 2022-06-29 | 2022-08-30 | 中国科学院上海有机化学研究所 | 一种轴手性卤代联芳基化合物及其制备方法 |
-
2023
- 2023-03-30 CN CN202310335538.7A patent/CN116535329B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109535018A (zh) * | 2018-12-10 | 2019-03-29 | 南方科技大学 | 一种手性磷酸盐催化合成联萘酚胺的方法 |
CN111217803A (zh) * | 2020-01-14 | 2020-06-02 | 商洛学院 | 一种小分子oled电子传输材料及其制备方法与应用 |
CN112920072A (zh) * | 2021-01-27 | 2021-06-08 | 山东大学 | Nobin类联芳基化合物及其合成方法 |
CN114957103A (zh) * | 2022-06-29 | 2022-08-30 | 中国科学院上海有机化学研究所 | 一种轴手性卤代联芳基化合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
LE ROUX, JEAN PIERRE 等: "1-Azidoisochromenes. A new route to 3, 1-benzoxazepines", 《JOURNAL OF HETEROCYCLIC CHEMISTRY》, vol. 18, no. 4, 30 June 1981 (1981-06-30), pages 847 - 849 * |
Also Published As
Publication number | Publication date |
---|---|
CN116535329B (zh) | 2024-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111777637B (zh) | 一种轴手性氧化吲哚衍生苯乙烯类膦催化剂及其制备方法与应用 | |
CN110452150B (zh) | 一种轴手性吲哚-萘类化合物及其制备方法 | |
CN110511259B (zh) | 环二核苷酸人工金属酶及其制备和催化不对称Friedel-Crafts反应的应用 | |
CN105772094A (zh) | 一种手性氮杂环卡宾类催化剂及其应用 | |
CN113735894B (zh) | 一类同时含有轴手性和中心手性的2,3-联烯醇类化合物及其制备方法和应用 | |
CN113979975B (zh) | 一种手性磷酸催化的芳基烯丙基叔醇动力学拆分方法 | |
Kumar et al. | Solvent-free synthesis of α-aminophosphonates: Cellulose-SO3H as an efficient catalyst | |
CN104592313B (zh) | 基于二茂铁的双功能氢键有机催化剂及其制备方法和应用 | |
CN116535329B (zh) | Nobin类轴手性联芳基化合物的合成方法及其化合物 | |
CN113549062A (zh) | 一种金鸡纳碱衍生的大位阻手性季铵盐相转移催化剂及其合成方法 | |
CN112898218B (zh) | 一锅法合成含三氟甲基噁唑酮类化合物的方法 | |
CN108059591B (zh) | 一种手性α-氟-β-乙炔基酮化合物的催化不对称合成方法 | |
CN111848322A (zh) | 一种轴手性氧化吲哚取代的苯乙烯类化合物及其拆分方法与应用 | |
CN109809967B (zh) | 一种合成手性醇的方法 | |
CN113173859B (zh) | 一种合成手性α-胺基醇化合物的方法 | |
CN102276616A (zh) | 一种呋喃[3,2-c]吡啶-4(5H)-酮类化合物合成方法 | |
CN112430228B (zh) | 一种手性2,3-二氢苯并[b]噻吩1,1-二氧化物、衍生物及制备方法 | |
CN110483323B (zh) | 一种不对称酰亚胺类化合物的制备方法 | |
CN114907404A (zh) | 5-(2-(二取代膦基)苯基)-1-烷基-1h-吡唑膦配体及其制备方法和应用 | |
CN115403494B (zh) | 一种温和条件下氧引发烯烃双功能化合成β-羟基砜衍生物的方法 | |
CN113121472B (zh) | 一种利用金配合物制备n-磺酰基四氢吡咯类化合物的方法 | |
CN106854125B (zh) | 一种制备含有两个手性中心α-氟-β-乙炔基酮化合物的方法 | |
Jia et al. | Highly Enantioselective Michael Addition of Ketone to Alkylidene Malonates Catalyzed by Binaphthyl Sulfonimides in Water | |
CN115057848B (zh) | 一种轴手性异吡喃酮-吲哚衍生物及其合成方法 | |
CN114213370B (zh) | 一种光诱导nhpi酯脱羧偶联合成烷基化富电子杂环芳烃方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |